Key clinical point: As initial treatment, hepatic arterial infusion chemotherapy (HAIC) effectuates a greater survival and radiological response than transarterial chemoembolization (TACE) among patients with infiltrative hepatocellular carcinoma (HCC).
Main finding: HIAC vs TACE led to a longer median overall survival ( 13.3 months vs 10.8 months; P = .043) and progression-free survival (7.8 months vs 4.0 months; P = .035) along with higher objective response (34.8% vs 11.8%; P = .001) and disease control (54.3% vs 36.8%; P = .028) rates.
Study details: Findings are from a retrospective real-world study including 160 adult patients with large infiltrative HCCs who underwent either HAIC (n=92) or TACE (n=68) as initial treatment.
Disclosures: The authors declared receiving no financial assistance for the study and having no potential conflict of interests.
Source: An C et al. Front Oncol. 2021 Dec 16. doi: 10.3389/fonc.2021.747496 .